- Home
- ABTS vs APLM Comparison
ABTS vs APLM Comparison
Compare ABTS & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- APLM
- Stock Information
- Founded
- ABTS 2010
- APLM 2016
- Country
- ABTS Hong Kong
- APLM United States
- Employees
- ABTS N/A
- APLM N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- APLM Blank Checks
- Sector
- ABTS Technology
- APLM Finance
- Exchange
- ABTS Nasdaq
- APLM Nasdaq
- Market Cap
- ABTS 16.0M
- APLM 15.6M
- IPO Year
- ABTS N/A
- APLM N/A
- Fundamental
- Price
- ABTS $0.46
- APLM $9.75
- Analyst Decision
- ABTS
- APLM Strong Buy
- Analyst Count
- ABTS 0
- APLM 2
- Target Price
- ABTS N/A
- APLM $425.00
- AVG Volume (30 Days)
- ABTS 88.2K
- APLM 102.2K
- Earning Date
- ABTS 12-31-2024
- APLM 02-15-2025
- Dividend Yield
- ABTS N/A
- APLM N/A
- EPS Growth
- ABTS N/A
- APLM N/A
- EPS
- ABTS N/A
- APLM N/A
- Revenue
- ABTS $5,343,888.00
- APLM $2,101,000.00
- Revenue This Year
- ABTS N/A
- APLM N/A
- Revenue Next Year
- ABTS N/A
- APLM N/A
- P/E Ratio
- ABTS N/A
- APLM N/A
- Revenue Growth
- ABTS 3970.67
- APLM 70.54
- 52 Week Low
- ABTS $0.38
- APLM $6.50
- 52 Week High
- ABTS $1.60
- APLM $105.00
- Technical
- Relative Strength Index (RSI)
- ABTS 40.47
- APLM 50.39
- Support Level
- ABTS $0.41
- APLM $7.23
- Resistance Level
- ABTS $0.58
- APLM $8.88
- Average True Range (ATR)
- ABTS 0.07
- APLM 1.37
- MACD
- ABTS -0.02
- APLM 0.21
- Stochastic Oscillator
- ABTS 14.52
- APLM 57.91
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.